VICL Vical Inc

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * ABERCROMBIE GEORGE B	2. Issuer Name and Ticker or Trading Symbol Brickell Biotech, Inc. [ BBI ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) CHIEF EXECUTIVE OFFICER
(Last)          (First)          (Middle) C/O BRICKELL BIOTECH, INC., 5777 CENTRAL AVENUE, SUITE 102	3. Date of Earliest Transaction (MM/DD/YYYY) 2/14/2020
(Street) BOULDER, CO 80301 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								7230	D
Common Stock								12082	I	By Spouse as Trustee
Common Stock								12082	I	By Spouse as Trustee
Common Stock								107030	I	By Self as Trustee

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$2.9							1/25/2011	1/25/2021	Common Stock	8630		8630	D
Stock Options	$6.37							2/14/2014	2/22/2024	Common Stock	2589		2589	D
Stock Options	$12.17							4/22/2015	4/22/2025	Common Stock	8630		8630	D
Stock Options	$12.17							12/15/2016	12/15/2026	Common Stock	3452		3452	D
Stock Options	$16.45							12/15/2019	12/15/2028	Common Stock	5178		5178	D
Stock Options	$4.76							8/30/2020	8/30/2029	Common Stock	34521		34521	D
Warrants	$10.36							8/30/2019	8/30/2019	Common Stock	3316		3316	D
Restricted Stock Units	$1.16	2/14/2020		A		2167		2/14/2020	2/13/2030	Common Stock	2167	$1.16	2167	D
Stock Options	$1.16	2/14/2020		A		8764		2/14/2020	2/13/2030	Common Stock	8764	$1.16	8764	D

Explanation of Responses:

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
ABERCROMBIE GEORGE B C/O BRICKELL BIOTECH, INC. 5777 CENTRAL AVENUE, SUITE 102 BOULDER, CO 80301	X		CHIEF EXECUTIVE OFFICER

Signatures
/s/ George B. Abercrombie		2/19/2020
**Signature of Reporting Person		Date